Physician

Cristi Lynn Aitelli, D.O.

According to 2025 Medicare claims, Cristi Aitelli, D.O. (NPI: 1578773511) practices medical oncology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Tarrant, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1033386578; TIN: 752131429) and primary practice location at 76132-4136. Aitelli is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Aitelli's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 544 traditional Medicare patients, billed 87,845 HCPCS/CPT codes, and received $1,587,457 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,628 prescription claims across 327 beneficiaries totaling $2,955,726 in drug costs, led by Ibrance (Palbociclib). 2021 DME data shows 12 claims. Open Payments data shows 8 records totaling $178. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,169,509 to $2,955,726. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,154 to $1,879.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	386	77,437	$1,141,342
2016	477	90,078	$1,545,560
2017	444	51,036	$989,205
2018	451	76,123	$1,115,976
2019	529	54,443	$935,592
2020	505	68,027	$1,146,580
2021	519	71,335	$1,262,152
2022	517	89,536	$1,402,411
2023	524	84,380	$1,418,456
2024	544	87,845	$1,587,457

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	223	1,479	$1,169,509
2016	264	1,709	$973,801
2017	247	1,823	$872,434
2018	244	1,313	$922,761
2019	250	1,289	$1,386,419
2020	230	1,375	$1,576,793
2021	261	1,360	$1,010,939
2022	267	1,273	$1,214,013
2023	280	1,356	$2,134,966
2024	327	1,628	$2,955,726

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	205	$87,110
2016	N/R	108	$42,110
2017	N/R	48	$12,234
2018	N/R	17	$1,019
2019	N/R	13	$735
2020	N/R	N/R	N/R
2021	N/R	12	$749
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	308	611	$91
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	122	190	$12
80053	Blood test, comprehensive group of blood chemicals	177	377	$10
36415	Insertion of needle into vein for collection of blood sample	254	625	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	244	518	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	32	896	$472,760
Pomalyst	Pomalidomide	15	413	$330,868
Revlimid	Lenalidomide	16	448	$305,305
Ninlaro	Ixazomib Citrate	19	532	$233,545
Tagrisso	Osimertinib Mesylate	13	390	$199,296

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$178	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Cristi Lynn Aitelli, D.O.?

Tedicare shows public-source Medicare data for Cristi Lynn Aitelli, D.O. (NPI 1578773511), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Cristi Lynn Aitelli, D.O. have ACO affiliation data?

Cristi Lynn Aitelli, D.O. is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Cristi Lynn Aitelli, D.O.?

Cristi Lynn Aitelli, D.O. is linked to TEXAS ONCOLOGY PA (billing NPI 1033386578) in the available physician profile data.

Does Cristi Lynn Aitelli, D.O. have Open Payments data?

Cristi Lynn Aitelli, D.O. has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.